Abstract:Key PointsThe development of simultaneous resistance to multiple drugs, with varying chemical structures and targets, is a major obstacle to effective cancer therapy.Studies indicate that there are three major mechanisms of multidrug resistance (MDR): decreased uptake of water-soluble drugs; various changes in cells that affect the ability of cytotoxic drugs to kill cells; and increased energy-dependent efflux of hydrophobic drugs.Removal of hydrophobic drugs from cells is the most commonly encountered mechanism of multidrug resistance (MDR), and ATP-binding cassette (ABC) transporters have a key role in this process.The ABC transporter family of proteins comprises seven subclasses that are labelled A–G, and these proteins have been shown to be essential for many cellular processes that require transport of substrates across cell membranes, with several members of this family being involved in the absorption, excretion and distribution of drugs.ABC transporters have broad substrate specificity, and the abundance of ABC transporter proteins goes some way to explaining the difficulties faced during the past 20 years when attempting to circumvent ABC-mediated MDR in vivo. Research has focused on the development of drugs that either evade efflux or inhibit the function of efflux transporters, and although progress in this area has been slow, the rationale for this approach is still strong.Several ABC transporters have been found to be overexpressed in cancer cell lines cultured under selective pressure, with at least 12 ABC transporters from four ABC subfamilies implicated in the drug resistance of cells maintained in tissue culture. Studies have shown that the major mechanism of MDR in most cultured cancer cells involves P-glycoprotein (Pgp; MDR1; ABCB1), multidrug resistance associated-protein 1 (MRP1, also known as ABCC1) or ABCG2.Despite significant advances in knowledge of the biochemistry and substrate specificity of ABC transporters since the first description of MDR, translation of this knowledge from the bench to the bedside has proved to be difficult. Only inhibitors of Pgp, and to a lesser extent MRP1 and ABCG2, have been evaluated in clinical trials, and the development of several inhibitors has been discontinued. However, some improved compounds are currently in clinical trials, and it is hoped that the lessons learned from earlier trials will improve the chance of success.Alternative strategies to overcome ABC-transporter-mediated MDR are also emerging, including engaging, evading or exploiting efflux-based resistance mechanisms.

Targeted efflux transporter inhibitors - A solution to improve poor cellular accumulation of anti-cancer agents

Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1

Targeting multidrug resistance in cancer

Exploring the potential of P-glycoprotein inhibitors in the targeted delivery of anti-cancer drugs: A comprehensive review

L-Type amino acid transporter 1 as a target for drug delivery

Effects Of Dihydropyridines And Pyridines On Multidrug Resistance Mediated By Breast Cancer Resistance Protein: In Vitro And In Vivo Studies

Evaluation of Novel Benzo-annelated 1,4-dihydropyridines as MDR Modulators in Cancer Cells

Mitochondrial targeting improves the selectivity of singlet‐oxygen cleavable prodrugs in NMIBC treatment

Computationally accelerated identification of P-glycoprotein inhibitors

Evaluation of dual P-gp-BCRP inhibitors as nanoparticle formulation

Membrane-Fusing Vehicles for Re-Sensitizing Transporter-Mediated Multiple-Drug Resistance in Cancer

Strategies to overcome cancer multidrug resistance (MDR) through targeting P-glycoprotein (ABCB1): An updated review

Dual Inhibition of P-gp and BCRP Improves Oral Topotecan Bioavailability in Rodents

Tenulin and isotenulin inhibit P-glycoprotein function and overcome multidrug resistance in cancer cells

The Therapeutic Potential of Targeting ABC Transporters to Combat Multi-Drug Resistance

Liposome-based approaches to overcome anticancer drug resistance

Advance in Efflux Pump Inhibitors for Multidrug Resistance

PepT1, ASBT-Linked Prodrug Strategy to Improve Oral Bioavailability and Tissue Targeting Distribution.

Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)

State of the Art of Overcoming Efflux Transporter Mediated Multidrug Resistance of Breast Cancer.

Targeted nanoliposomes of oncogenic protein degraders: Significant inhibition of tumor in lung-cancer bearing mice